tradingkey.logo

10X Genomics Inc

TXG
查看详细走势图
20.350USD
+1.060+5.50%
交易中 美东报价延迟15分钟
2.58B总市值
亏损市盈率 TTM

10X Genomics Inc

20.350
+1.060+5.50%
盘中分时
1分
30分
1小时
日k
周k
月k
日k

今天

+5.50%

5天

+24.77%

1月

+16.49%

6月

+66.12%

今年开始到现在

+24.77%

1年

+28.55%

查看详细走势图

TradingKey 10X Genomics Inc股票评分

单位: USD 更新时间: 2026-01-08

操作建议

10X Genomics Inc当前公司基本面数据相对非常健康,增长潜力很大。当前估值合理,在医疗设备与耗材行业排名40/208位。机构持股占比非常高,近一月多位分析师给出公司评级为持有。最高目标价17.27。中期看,股价处于上升通道。近一个月,市场表现较强,技术面和基本面综合得分较高,较强的走势得到基本面和技术面的印证。目前股价在压力位和支撑位之间,可以做区间波段操作。

10X Genomics Inc评分

相关信息

行业排名
40 / 208
全市场排名
112 / 4563
所属行业
医疗设备与耗材

压力支撑

由于公司未披露,未能获取相关数据

多维评测

本期评分
上期评分

公司舆情

过去24小时
热度

过冷
过热
看空

10X Genomics Inc亮点

亮点风险
10x Genomics, Inc. is a life science technology company. The Company's integrated solutions include instruments, consumables and software for single cell and spatial biology systems. Its single cell portfolio, powered by Chromium platform, includes its Chromium X Series, Chromium Connect and legacy Chromium Controller instruments, microfluidic chips and related consumables, which enables throughput analysis of individual biological components. Its Visium platform enables researchers to understand the spatial positions of biological analytes within tissues at high resolution. Its Xenium platform for in situ analysis is designed to give scientists the ability to not only locate and type cells in their tissue context. Its products include Chromium Single Cell Gene Expression, Chromium Single Cell Gene Expression Flex, Chromium Single Cell Immune Profiling, Chromium Single Cell assay for transposase accessible chromatin (ATAC), Visium Spatial Gene Expression, and others.
业绩高增长
公司营业收入稳步增长,连续3年增长18.28%
估值低估
公司最新PE估值-30.93,处于3年历史低位
机构减仓
最新机构持股125.94M股,环比减少11.00%
Hotchkis & Wiley持仓
明星投资者Hotchkis & Wiley持仓,最新持仓市值2.42K
活跃度降低
近期活跃度降低,过去20天平均换手率0.35

分析师目标

根据 18 位分析师
持有
评级
17.267
目标均价
-5.75%
涨幅空间
数据免责声明:分析师评级与目标价由LSEG提供,仅供参考,不应当作投资建议

10X Genomics Inc新闻

即将为您带来更多新闻,敬请期待。。。

财务指标

每股收益

由于公司未披露,未能获取相关数据

营业总收入

由于公司未披露,未能获取相关数据

10X Genomics Inc简介

10x Genomics, Inc. is a life science technology company. The Company's integrated solutions include instruments, consumables and software for single cell and spatial biology systems. Its single cell portfolio, powered by Chromium platform, includes its Chromium X Series, Chromium Connect and legacy Chromium Controller instruments, microfluidic chips and related consumables, which enables throughput analysis of individual biological components. Its Visium platform enables researchers to understand the spatial positions of biological analytes within tissues at high resolution. Its Xenium platform for in situ analysis is designed to give scientists the ability to not only locate and type cells in their tissue context. Its products include Chromium Single Cell Gene Expression, Chromium Single Cell Gene Expression Flex, Chromium Single Cell Immune Profiling, Chromium Single Cell assay for transposase accessible chromatin (ATAC), Visium Spatial Gene Expression, and others.
公司代码TXG
公司10X Genomics Inc
CEOSaxonov (Serge Wilson)
网址https://www.10xgenomics.com/

常见问题

10X Genomics Inc(TXG)的当前股价是多少?

10X Genomics Inc(TXG)的当前股价是 20.350。

10X Genomics Inc的股票代码是什么?

10X Genomics Inc的股票代码是TXG。

10X Genomics Inc股票的52周最高点是多少?

10X Genomics Inc股票的52周最高点是20.340。

10X Genomics Inc股票的52周最低点是多少?

10X Genomics Inc股票的52周最低点是6.780。

10X Genomics Inc的市值是多少?

10X Genomics Inc的市值是2.58B。

10X Genomics Inc的净利润是多少?

10X Genomics Inc的净利润为-182.63M。

现在10X Genomics Inc(TXG)的股票是买入、持有还是卖出?

根据分析师评级,10X Genomics Inc(TXG)的总体评级为持有,目标价格为17.267。

10X Genomics Inc(TXG)股票的每股收益(EPS TTM)是多少

10X Genomics Inc(TXG)股票的每股收益(EPS TTM)是-0.624。
KeyAI